Saurav Chatterjee - 15 May 2024 Form 4 Insider Report for Augmedix, Inc.

Role
CHIEF TECHNOLOGY OFFICER
Signature
/s/ Todd Holvick, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 May 2024
Net transactions value
-$2,103
Form type
4
Filing time
17 May 2024, 21:00:27 UTC
Previous filing
27 Feb 2024
Next filing
19 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUGX Common Stock Options Exercise +4,688 4,688 15 May 2024 Direct F1
transaction AUGX Common Stock Sale $2,103 -1,767 -38% $1.19 2,921 15 May 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUGX Restricted Stock Units Options Exercise $0 -4,688 -6.3% $0.000000 70,312 15 May 2024 Common Stock 4,688 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 Represents an original award of 75,000 RSUs to acquire shares of the Company's common stock. The RSU was granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. One-sixteenth (1/16th) of the RSU will vest quarterly in equal increments over four (4) years commencing on 02/15/2024, with the first one-sixteenth (1/16th) vesting on 5/15/2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.